long term use of glp 1 agonists As GLP-1 receptor continue expanding across obesity, diabetes, fatty liver disease, and cardiometabolic care, clinicians are increasingly confronting a pressing question: Does long-term lead to tolerance, or do apparent “diminishing The expanding role of GLP-1

M., Ryan D

Move over, Stevia

In summary, the neuroprotective effects of GLP-1RAs have been demonstrated in various in vivo models of diabetes, aging, AD, and PD

Interestingly, higher incidence of diabetic retinopathy (DR) complications was noted in patients taking semaglutide (3.0%) compared to placebo (1.5%) in clinical trials, with greater risk in those with a history of DR [32]

Where Zepbound fits in Zepbound has quickly become one of the most talked-about medications in obesity care

However, when used with insulin or sulfonylureas, dose adjustments of these agents may be needed to prevent hypoglycemia, as with all GLP-1 receptor agonists